Its integration into mesoporous silica nanoparticles has shown promise in resveratrol delivery for triple-negative breast cancer, where selective activation by the urokinase-type plasminogen activator (uPA) ensures localized drug release. Here, PLAU is linked to triple-negative breast carcinoma.